Bladder Botox denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for bladder botox are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Bladder Botox as "Not FDA-Approved" — and Why That May Be Wrong

OnabotulinumtoxinA (Botox) carries FDA approval for specific overactive bladder and neurogenic detrusor overactivity indications. When Humana issues a "not FDA-approved" denial for bladder Botox, the denial is frequently a classification or coding error — the claim was submitted under a procedure code or indication description that did not clearly link to an approved use, or the denial template was applied without verifying the specific indication.

Before appealing, confirm with your prescriber exactly which FDA-approved indication applies to your case. The FDA-approved prescribing label lists the approved bladder indications precisely; your appeal should cite that label language directly.

## Your Federal Appeal Rights

Under ACA §2719, non-grandfathered individual and group health plans must provide internal appeal and external review rights. ERISA §503 requires full-and-fair review for employer-sponsored plans. You generally have up to 180 days from the denial notice to file an internal appeal. If the internal appeal fails, you may request external review by an Independent Review Organization (IRO) — typically within four months of the final internal denial. If your condition is urgent, request expedited external review, which must be decided within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Chart notes and urodynamic or clinical documentation establishing the specific approved diagnosis (e.g., overactive bladder with urinary incontinence or neurogenic detrusor overactivity).
• Prescriber letter: A detailed medical-necessity letter from the urologist or urogynecologist citing the exact FDA-approved indication, why conservative measures have been inadequate, and how the patient's clinical picture meets the approved use.
• FDA label excerpt: Attach the relevant indication section from the current FDA-approved prescribing information — this directly rebuts a "not approved" denial.
• Prior claim and EOB: Identify the exact code(s) Humana used to issue the denial so your prescriber can correct any submission error.

## Criteria-Mapping Structure

Copy each requirement listed in Humana's denial letter and in the FDA prescribing label's indication section. Next to each requirement, write the specific chart fact that satisfies it — date of diagnosis, relevant test results, name of treating clinician. Submit this as a structured table or numbered list so the reviewer can check off each element without hunting through the record.

## What to Expect

Internal appeals are typically decided within 30 days (non-urgent) or 72 hours (expedited). Keep a written log of every submission with dates and confirmation numbers. If Humana upholds the denial after internal review, the IRO external review is your next step and is legally binding on the plan.